Market Overview:
The global blood plasma fractionation market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing demand for blood plasma products for various applications such as immunity, therapy, and surgery. In addition, the increasing prevalence of chronic diseases is also contributing to the growth of this market. Based on type, albumin accounted for the largest share of the global blood plasma fractionation market in 2017. This can be attributed to its wide range of applications in various industries such as food & beverage, pharmaceuticals, and cosmetics.
Product Definition:
Blood plasma fractionation is the process of separating blood plasma from other blood components. The separated plasma can then be used for a variety of medical treatments, including transfusions and dialysis. Plasma is important because it contains proteins that help the body fight infection and clotting factors that help prevent bleeding.
Albumin:
Albumin is a plasma protein and it's the most abundant blood constituent. It accounts for approximately 45% of total proteins in human blood. Plasma contains around 40-45% of albumin along with other proteins such as fibrinogen, fibrogammin, and immunoglobulins.
Immune Globulin:
Immune Globulin is a product that is used to fractionate plasma. It helps in the separation of proteins, cells and other particles from blood. The immune system uses antibodies as well as cell-mediated responses for protection against pathogens and foreign substances. The antibodies bind themselves to harmful substances present in the body and remove them out of the circulation; this also includes some cancer cells which are usually found in an unhealthy person's body. This process is called immunization or antibody binding.
Application Insights:
Based on the application, the global blood plasma fractionation market is segmented into immunity, therapy and surgery. The immunity segment dominated the overall market in terms of revenue share in 2017. Immunity products are used for infectious diseases treatment and autoimmune disorders. Increasing immunization rates against a number of infectious diseases including cholera, typhoid, measles etc., due to wide scale availability of vaccines is expected to drive demand over the forecast period.
The growing prevalence of chronic conditions such as cancer and autoimmune disorders coupled with rising geriatric population across regions is anticipated to drive demand for blood plasma fractionation over the forecast period. In addition, increasing R&D activities pertaining to immune-based therapies & stem cell transplantation which involves usage of blood components will further boost product consumption during this period (2017-2030).
Regional Analysis:
North America dominated the global blood plasma fractionation market in 2017. The presence of a large number of players coupled with high R&D investment by them is one of the major factors contributing to its large share. In addition, increasing incidence and prevalence of chronic diseases are also expected to drive this segment during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure, growing patient awareness levels regarding available therapies, and availability of effective products at affordable prices. Moreover, government initiatives encouraging R&D activities are likely to boost regional market growth in near future.
Infectious diseases accounted for majority shares in terms of mortality rates across developing countries such as India.
Growth Factors:
- Increasing incidence of chronic diseases: The increasing incidence of chronic diseases such as cancer, autoimmune disorders, and blood-related disorders is expected to drive the demand for blood plasma fractionation products and services.
- Technological advancements: The development of novel technologies for the separation and purification of blood plasma proteins is expected to propel the growth of the market.
- Rising demand from emerging economies: The growing population and rising income levels in emerging economies are expected to create a high demand for blood plasma fractionation products and services in these regions.
- Growing awareness about benefits of blood plasma fractionation: There is a growing awareness among healthcare professionals about the benefits offered by various types of blood plasma fractions, which is likely to boost market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood Plasma Fractionation Market Research Report
By Type
Albumin, Immune Globulin, Coagulation Factor
By Application
Immunity, Therapy, Surgery
By Companies
GE Healthcare, Pall Corporation, Baxter, CSL, Grifols, Octapharma, BPL, Kedrion, Mitsubishi Tanabe, CBOP, GE Healthcare, Hualan Bio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Blood Plasma Fractionation Market Report Segments:
The global Blood Plasma Fractionation market is segmented on the basis of:
Types
Albumin, Immune Globulin, Coagulation Factor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunity, Therapy, Surgery
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GE Healthcare
- Pall Corporation
- Baxter
- CSL
- Grifols
- Octapharma
- BPL
- Kedrion
- Mitsubishi Tanabe
- CBOP
- GE Healthcare
- Hualan Bio
Highlights of The Blood Plasma Fractionation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Albumin
- Immune Globulin
- Coagulation Factor
- By Application:
- Immunity
- Therapy
- Surgery
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood Plasma Fractionation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Blood plasma fractionation is a process of separating the blood into its various components, including red blood cells, white blood cells, and plasma. This is done to allow for more accurate analysis of the different components and to improve patient care.
Some of the major players in the blood plasma fractionation market are GE Healthcare, Pall Corporation, Baxter, CSL, Grifols, Octapharma, BPL, Kedrion, Mitsubishi Tanabe, CBOP, GE Healthcare, Hualan Bio.
The blood plasma fractionation market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Blood Plasma Fractionation Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Blood Plasma Fractionation Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Blood Plasma Fractionation Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Blood Plasma Fractionation Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Blood Plasma Fractionation Market Size & Forecast, 2018-2028
4.5.1 Blood Plasma Fractionation Market Size and Y-o-Y Growth
4.5.2 Blood Plasma Fractionation Market Absolute $ Opportunity
Chapter 5 Global Blood Plasma Fractionation Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Blood Plasma Fractionation Market Size Forecast by Type
5.2.1 Albumin
5.2.2 Immune Globulin
5.2.3 Coagulation Factor
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Blood Plasma Fractionation Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Blood Plasma Fractionation Market Size Forecast by Applications
6.2.1 Immunity
6.2.2 Therapy
6.2.3 Surgery
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Blood Plasma Fractionation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Blood Plasma Fractionation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Blood Plasma Fractionation Analysis and Forecast
9.1 Introduction
9.2 North America Blood Plasma Fractionation Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Blood Plasma Fractionation Market Size Forecast by Type
9.6.1 Albumin
9.6.2 Immune Globulin
9.6.3 Coagulation Factor
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Blood Plasma Fractionation Market Size Forecast by Applications
9.10.1 Immunity
9.10.2 Therapy
9.10.3 Surgery
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Blood Plasma Fractionation Analysis and Forecast
10.1 Introduction
10.2 Europe Blood Plasma Fractionation Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Blood Plasma Fractionation Market Size Forecast by Type
10.6.1 Albumin
10.6.2 Immune Globulin
10.6.3 Coagulation Factor
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Blood Plasma Fractionation Market Size Forecast by Applications
10.10.1 Immunity
10.10.2 Therapy
10.10.3 Surgery
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Blood Plasma Fractionation Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Blood Plasma Fractionation Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Blood Plasma Fractionation Market Size Forecast by Type
11.6.1 Albumin
11.6.2 Immune Globulin
11.6.3 Coagulation Factor
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Blood Plasma Fractionation Market Size Forecast by Applications
11.10.1 Immunity
11.10.2 Therapy
11.10.3 Surgery
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Blood Plasma Fractionation Analysis and Forecast
12.1 Introduction
12.2 Latin America Blood Plasma Fractionation Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Blood Plasma Fractionation Market Size Forecast by Type
12.6.1 Albumin
12.6.2 Immune Globulin
12.6.3 Coagulation Factor
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Blood Plasma Fractionation Market Size Forecast by Applications
12.10.1 Immunity
12.10.2 Therapy
12.10.3 Surgery
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Blood Plasma Fractionation Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Blood Plasma Fractionation Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Blood Plasma Fractionation Market Size Forecast by Type
13.6.1 Albumin
13.6.2 Immune Globulin
13.6.3 Coagulation Factor
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Blood Plasma Fractionation Market Size Forecast by Applications
13.10.1 Immunity
13.10.2 Therapy
13.10.3 Surgery
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Blood Plasma Fractionation Market: Competitive Dashboard
14.2 Global Blood Plasma Fractionation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GE Healthcare
14.3.2 Pall Corporation
14.3.3 Baxter
14.3.4 CSL
14.3.5 Grifols
14.3.6 Octapharma
14.3.7 BPL
14.3.8 Kedrion
14.3.9 Mitsubishi Tanabe
14.3.10 CBOP
14.3.11 GE Healthcare
14.3.12 Hualan Bio
